Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.56 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157047 | 0.81 | MAPK1 (0.58) | MTNR1AMTNR1BCCR2KMT2AMEN1 | |
| SCHEMBL26473 | 0.78 | MTNR1B (0.67) | MTNR1AMTNR1BCCR2KMT2ANTRK1 | |
| SCHEMBL6778354 | 0.77 | MTNR1B (0.66) | MTNR1AMTNR1BCCR2KMT2ANTRK1 | |
| SCHEMBL6775247 | 0.77 | CCR2 (0.65) | MTNR1AMTNR1BCCR2KMT2APLA2G2A | |
| SCHEMBL21803739 | 0.76 | GAA (0.45) | KMT2AMEN1MAPTCYP19A1 | |
| SCHEMBL13632218 | 0.75 | MTNR1B (0.60) | MTNR1AMTNR1BCCR2KMT2AMEN1 | |
| SCHEMBL2156774 | 0.75 | MTNR1A (0.52) | MTNR1AMTNR1BCCR2KMT2AMEN1 | |
| SCHEMBL4797082 | 0.74 | CCR2 (0.58) | CCR2KMT2AMEN1CYP19A1SMN1; SMN2 | |
| SCHEMBL14154245 | 0.74 | MTNR1A (0.56) | MTNR1AMTNR1BCCR2KMT2ANTRK1 | |
| SCHEMBL2156783 | 0.74 | CCR2 (0.52) | MTNR1AMTNR1BCCR2KMT2ANTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-0950661-B1 | Substituted tricyclics useful in sPLA2 induced diseases | LILLY CO ELI (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1156050-A2 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0950661-A1 | Substituted tricyclics useful in sPLA2 induced diseases | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |